These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: In vitro evaluations of aminopenicillin/beta-lactamase inhibitor combinations. Author: Jones RN. Journal: Drugs; 1988; 35 Suppl 7():17-26. PubMed ID: 3265377. Abstract: Sulbactam/ampicillin (Unasyn) possesses the antimicrobial activity of each drug plus the synergistic action and qualities of sulbactam used as a beta-lactamase inhibitor. The combination has a spectrum of activity against many Enterobacteriaceae, Haemophilus species, Branhamella catarrhalis, pathogenic Neisseria species, Acinetobacter anitratus, some pseudomonads, nearly all anaerobes (including Bacteroides), Staphylococcus species, streptococci, and the enterococci. Sulbactam/ampicillin was found to be bactericidal, and its minimum inhibitory concentrations (MICs) affected only by high inoculum concentrations (greater than 10(6) CFU/ml). Fixed ratio in vitro susceptibility tests appear to be preferred, since they best approximate clinical formulations and drug pharmacokinetics. The ratio of 1:1 has been studied, but other ratios such as 1:2 (sulbactam/ampicillin) should be evaluated to promote greater test accuracy. Separate interpretive criteria for most Gram-negative bacteria, Haemophilus, and staphylococci appear unnecessary for some tests.[Abstract] [Full Text] [Related] [New Search]